NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Other board meeting date announcements
All →Bajaj Steel Industries Board Meeting Date
Bajaj Steel will hold a board meeting on 6 November 2026 to approve unaudited quarterly and half-year results. The trading window stays closed.
Aashka Hospitals Board Meeting Date
Aashka Hospitals Ltd informed BSE of a board meeting on 05 November 2026 to consider unaudited standalone financial results for the half year ended September 30, 2026. The filing is a routine board meeting intimation.
ECS Biztech Board Meeting Date
ECS Biztech schedules a 4 November 2026 board meeting to approve September 2026 quarter and half-year standalone results. Trading window stays closed until 48 hours post-results.
Orchasp Board Meeting Date
Orchasp will hold a board meeting on November 11, 2026 to approve unaudited half-yearly results. The trading window stays closed until November 13, 2026.
Vintage Securities Board Meeting Date
Vintage Securities will hold a board meeting on 05 November 2026 to consider unaudited standalone half-yearly results for September 2026. The meeting date is advance notice and the trading window closes from 01 October 2026.
SVP Global Textiles Board Meeting Date
SVP Global Textiles schedules a 9 November 2026 board meeting to consider September 2026 quarter results. Trading window stays closed until 48 hours after results.